Myeloproliferative Neoplasms (MPN)

Latest News

The investigators found that people with MPNs and at least one CVRF had an increased risk of both death and arterial or venous thrombosis. | Image credit: Dr_Microbe - stock.adobe.com

Cardiovascular Risk Factors Impact Outcomes in MPNs

April 21st 2025

Cardiovascular risk factors increase the risk of arterial and venous thrombosis in patients with myeloproliferative neoplasms, a study found.

In Charleston, West Virginia, Tracking MPN Symptoms Becomes a Priority

By Mary Caffrey

January 17th 2025

Supportive Care | Image credit: Pexels photo

Kent Hospital MPN Initiative Focuses on Supportive Care

By Mary Caffrey

January 16th 2025

ACCC Helps Share Best Practices for MPN Care

By Mary Caffrey

January 15th 2025

Ruxolitinib Combinations in MPNs: Updates From ASH

By Mary Caffrey

January 8th 2025

AJMC Provides Myelofibrosis Guideline Updates

Watch the series now!

Watch Now

AJMC Provides Myelofibrosis Guideline Updates

More News

Distressed young woman of color | Image credit: Diego Cervo - stock.adobe.com

March 8th 2024

AYA With MPN Face Psychological Needs That Are Poorly Understood

Laura Joszt, MA

A review of research confirms that adolescents and young adults (AYA) with myeloproliferative neoplasms (MPN) face psychological burdens but the exact burden is poorly understood.

March 6th 2024

NCCN Lists Ropeginterferon Alfa-2B as Preferred First-Line Cytoreductive Therapy for Polycythemia Vera

Ashling Wahner

The National Comprehensive Cancer Network (NCCN) recommends ropeginterferon alfa-2b as first-line cytoreductive therapy for polycythemia vera.

Screenshot of Jennifer Vaughn, MD, in a Zoom video interview

March 1st 2024

Dr Jennifer Vaughn: Patients With MPN, MDS Should Discuss Long-Term Priorities Upfront

Laura Joszt, MA Justina Petrullo

For many patients with myeloproliferative neoplasms (MPNs) and myelodysplastic syndromes (MDS), their disease will be chronic, giving them a long-term cancer experience, said Jennifer Vaughn, MD, of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital.

Doctor Measuring arterial blood pressure man patient Health care in hospital | joyfotoliakid - stock.adobe.com

December 7th 2023

Reducing Cardiovascular Risk in Patients With Polycythemia Vera

Pearl Steinzor

Polycythemia vera (PV) therapy should aim to identify cardiovascular risk factors, according to one review.

Diagnosis of Myelofibrosis. Laboratory blood bottle (tube), glass slide with blood smear, hematology test, stethoscope lying on notebook with printed text hematological diagnosis of Myelofibrosis | shidlovski - stock.adobe.com

November 17th 2023

Enhancing Outcomes and Quality of Life for Patients With Myelofibrosis

Pearl Steinzor

A phase 3 trial in symptomatic and anemic patients with myelofibrosis (MF) met its primary end point, seeing a significant symptom reduction at 24 weeks with momelotinib vs danazol.

Rare diseases inscription words. Medical concept of unusual disorders | valiantsin - stock.adobe.com

October 24th 2023

The Effects of Aging on Profiling Epigenetic Changes in Myeloproliferative Neoplasms

Pearl Steinzor

Researchers identified distinct patterns of epigenetic dysregulation in myeloproliferative neoplasms.

Myeloproliferative Disorders. Myeloproliferative Disorders disease blood test inmedical laboratory: © luchschenF - stock.adobe.com

May 15th 2023

Review Highlights Features, Treatment of Budd-Chiari Syndrome in MPNs

Gianna Melillo

Budd-Chiari syndrome and myeloproliferative neoplasms (MPNs) are rare, which means available data are limited.

November 12th 2020

Integrative Medicine Shows Benefits for Patients With MPNs

Jaime Rosenberg

A recent survey of patients with myeloproliferative neoplasms found integrative medicine interventions improved symptom burden, fatigue, depression, and improved quality of life.

<1 2

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions